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Sudden unexpected death (SUD) has been associated with low or undetectable concentrations of antiepileptic drugs in patients 
with epilepsy suggesting that a sudden fall in plasma levels of these drugs might be a critical factor for the occurrence of 
SUD. We studied the changes in arrhythmia profile and heart-rate variability, during abrupt withdrawal of carbamazepine and 
phenytoin treatment in 10 patients with side effects on these drugs. Continuous ECG recording and daily measurements of drug 
plasma concentrations were performed from the last day of steady-state treatment and the following 4 days. Three patients 
had a IO-fold increase in ventricular premature beats. In addition, there was a significant reduction in heart-rate variability, 
assessed over 24 hours, in both the time (SDNN index, P = 0.03) and frequency domains from days 1-5. In the frequency 
domain analysis there was a significant reduction in total power (P = 0.01). very-low-frequency power (P = 0.004) and in 
low-frequency (LF) power (P = 0.01). Similar reductions in heart-r&e variability and increases in ventricular automaticity 
have been associated with increased mortality in other patient groups. Two factors that might contribute to the increased rate 
of SUD in patients with epilepsy have thus been identified. 
Kq words: antiepileptic drugs; cardiac arrhythmias; heart-rate variability. 
INTRODUCTION 
Sudden unexpected, unexplained death (SUD) is more 
common in patients with epilepsy compared with 
the general population I**. The mechanism for SW 
in epilepsy is unclear, but there are several theo- 
ries such as: cardiac tachy- or bradyarrhythmias re- 
lated to paroxysmal autonomic dysfunction; respi- 
ratory arrest3 and neurogenic pulmonary oedema4; 
events occurring in connection with overt or sub- 
clinical seizures. Low or undetectable post-mortem 
blood concentrations of antiepileptic drugs has been 
a frequent finding in cases of SW (reviewed in $6). 
The relevance of these findings has been questioned 
on methodological grounds, but they have raised a 
question as to the role of sudden drug withdrawal or 
non-compliance as precipitating factors for SW. 
The antiepileptic drugs carbamazepine and pheny- 
toin are sodium-channel blockers with a membrane- 
stabilizing effect in the central nervous system7 
as well as in the cardiac conduction system and 
myocardium . 8-1o Carbamazepine may induce car- 
diac bradyarrhythmias, which has caused safety con- 
cerns’ I* ‘* and phenytoin has been used and classified 
as an antiarrhythmic drug”. A sudden withdrawal 
of such cardioactive drugs might theoretically induce 
both direct and indirect cardiac changes of relevance 
for SW unrelated to seizure activity. We therefore 
conducted a prospective study to assess the changes 
of the arrhythmia profile and the activity of the au- 
tonomic nervous system, as reflected by changes in 
heart-rate variability in connection with abrupt with- 
drawal of carbamazepine or phenytoin treatment. 
PATIENTS AND METHODS 
Study population 
Ten patients (6 men) with a mean age of 66 (SD& 10) 
years were included. All were under long-term treat- 
ment with carbamazepine or phenytoin, and in all an 
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Table 1: Clinical data. 
Pat no/ 
age/sex 
1/64/F 
Indication for 
CBZ or PHT 
Complex partial 
seizures 
Drug, dose [mg/dayl. 
concentration 
[pmol/ll Reason for drug Other drugs 
at withdrawal withdrawal Other diseases [dose/day in mg] 
CBiXOOl26 Allergic skin reaction Hypertension Prooranol (80) 
Ben’droflumethiazide (2.5) 
Potassium chloride (750) 
2/65/M 
3/76/F 
4/76/M 
5/59/M 
6/65/F 
7l43lM 
8/60/M 
9/55/F 
lOfl5fM 
Complex partial CBZl600/23 
Simple partial 
seizures 
PHTl300130 
Complex partial 
seizures 
PHTl350l79 
Complex partial 
seizures 
CBZ/400/18 
Trigeminal neuralgia CBZ1900/2 1 
Partial seizures with CBZ/700/36 
secondary 
generalization 
Complex partial 
seizures 
CBZ/600/16 
Complex partial 
seizures 
CBZ/400/17 
Generalized tonic- CBZl600/27 
clonic seizures 
Diarrhoea 
Suspicion of tachy- 
brady syndrome 
Sinus bradycardia 
(2 45 beats/min) 
Sinus bradycardia 
(140 beats/min) 
Lack of effect 
Sinus bradycardia 
(2 40 beats/min) 
Intermittent second 
degree 
AV-block with 2: 1 
conduction 
Sinus bradycardia 
(1 35 beats/min) 
Sinus arrests (5 3 set) 
AV-block I and RBBB 
Hypertension 
Diabetes mellitus 
- 
- 
- 
Ankylosing spondylitis 
Manic-depressive 
disorder 
Hypothyreosis 
Diabetes mellitus 
Congestive heart failure 
Amiloride (2.5) 
Hydrochlorothiazide (25) 
Glibenclamide (3.5) 
Flupentixol (I) 
- 
- 
Ketoprofen (33) 
- 
Lithium (168) 
Levothyroxine (0. I) 
Levomepromazine (25) 
Glibenclamide (7) 
Furosemide (80) 
Amiloride (5) 
Abbreviations: AV = atrioventricular; CBZ = carbamazepine; F = female: M = male; PHT = phenytoin; RBBB = right bundle branch 
block. 
abrupt withdrawal of the antiepileptic drugs was jus- 
tified on clinical grounds. Nine had suspected side ef- 
fects of carbamazepine (n = 7) or phenytoin (n = 2). 
The reason for withdrawal was extracardiac adverse 
effects in two patients (pts 1, 2). In three patients 
(pts 4, 9, 10) the type of cerebral symptoms and 
electrocardiography (ECG) suggested bradycardia- 
related symptoms that might have been provoked 
or exaggerated by the drugs. Three patients (pts 5, 
7, 8) had asymptomatic bradycardias recognized in 
connection with a 24-hour ECG prevalence study of 
arrhythmias in a population of patients with epilep- 
tic seizures with a normal standard 12-lead surface 
ECG and without symptoms suggestive of arrhyth- 
mias”. Patient 3 was initially suspected to have a 
tachycardia bradycardia syndrome, but was found to 
have paroxysmal atria1 flutter without bradycardia. 
The remaining patient (pt 6) had trigeminal neuralgia 
and was on carbamazepine, which was ineffective 
and motivated a change in therapy. 
Except for well-regulated mild hypertension in two 
patients and a clinically compensated congestive heart 
failure in one patient, there was no evidence of car- 
diovascular or clinically significant structural heart 
disease, Table 1. 
All patients were hospitalized for safety reasons, 
and after this study further medical investigations or 
treatment were started. During the 5-day study pe- 
riod, all patients carried a two-channel ECG cassette 
recorder (Medilog II, Oxford Medical Systems). An 
electrode position similar to VI and V6 in a 1Zlead 
ECG was used for assessment. The recording quality 
was checked with regard to stability and ability to de- 
tect P-waves. All medication was unchanged during 
the first 24 hours. The antiepileptic drug was then 
withdrawn and plasma concentrations of the drugs 
were followed daily. Plasma levels of carbamazepine 
and phenytoin were determined using a slight modi- 
fication of the high-performance liquid chromatogra- 
phy previously described 13. All tapes were analysed 
as follows. 
Arrhythmias. The tapes were first automatically 
screened for the following arrhythmias: sinus pauses 
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2 1.5 seconds, second- and third-degree atrioventric- 
ular block, ventricular premature beats and ventricular 
tachycardias as well as supraventricular tachyarrhyth- 
mias. The results were then manually checked in two 
steps, first by a skilled nurse for determination of the 
correct classification of tachy- and bradyarrhythmias 
as well as for premature beats. In addition, one of 
the cardiologists reviewed the classification of all ar- 
rhythmias. 
The following definitions were used. A sinus pause 
was an RR interval 1 1.5 seconds, excluding (1) com- 
pensatory pauses following premature QRS com- 
plexes, (2) posttachycardia pauses, i.e. a pause pre- 
ceded by a brief increase in heart rate and followed 
by a gradual return in heart rate to the pre-pause level, 
and (3) pauses due to a blocked premature P-wave. 
Conduction intervals. All recordings were printed 
onto paper with a speed of 50 mm/second, blind 
coded, and the measurements were then made by a 
person, who could identify each individual, for the 
purpose of performing all measurements in the same 
channel, but who was unaware of the order of the five 
recordings. All five recordings were analysed at the 
same time for each individual, in order to have the 
same definition of all measured points. The conduc- 
tion intervals were measured during the same time pe- 
riod every day. A stable recording period was chosen 
between 5.30 and 6.30 pm. All measurements were 
performed on a digitizer table (Kurta IS/ADB, Kurta 
Corporation, USA) working in point mode with a res- 
olution of f0.002 mm. The measured intervals were: 
the PP, RR, PQ, QRS and QT intervals, which were 
calculated as the mean of three intervals. The JT in- 
terval was obtained by subtracting the QRS from the 
QT interval. The JT and QT intervals were also heart- 
rate corrected according to the method by Bazett 
(QTc = QT/m in seconds and JTc = JT/m 
in seconds)14. The mean RR interval (the inverse of 
the mean heart rate) of 24 hours was calculated in the 
following way: the mean RR interval of every 500- 
beat segment was determined and then a mean of all 
segments over 24 hours was calculated. 
Heart-rate variability. This was analysed in the time 
and frequency domains. The RR-intervaIs and their 
corresponding classifications of QRS complexes were 
exported as an ASCII text file from the commercially 
available ECG-analyser in the Aspect Holter System 
(Daltek Biomedical, Sweden). The RR-intervals were 
expressed as centiseconds with an accuracy of f 1 
centisecond. The exported text files were fed into a 
custom-made software running under MS-Windows. 
Data was presented in segments of 500 beats each. 
The RR-intervals were checked for the occurrence of 
non-normal beats. The non-normal beats were deleted 
and interpolated using cubic spline interpolation. In 
addition, sudden long RR intervals, i.e. dropped beats 
or pauses, were interpolated. The periods of raw 
RR-data were corrected for linear trend using linear 
regression and subtraction of the mean of all RR- 
intervals in the same segment. 
Segments containing more than 4% non-normal 
beats were excluded. If more than 50% of the seg- 
ments per time period (daytime, night-time or during 
24 hours) had to be excluded for this reason the whole 
time period was withdrawn from analyses. 
The time-domain measures; mean RR interval, 
standard deviation of the mean (SD-RR) and the vari- 
ance of RR were determined for each segment. The 
SD of normal RR intervals (NN intervals) were cal- 
culated and defined as the mean of the SD of all 
segments of a 24-hour ECG recording, which is the 
SDNN index15. 
In the frequency-domain analysis, the power at dif- 
ferent frequencies was determined using an autore- 
gressive spectral analysis method16. The model or- 
der of the autoregressive spectral analysis (number 
of coefficients in the polynomial describing the time 
series) was constantly set to 18. The following fre- 
quency domain indices were used: VLF, very-low- 
frequency power, 0.0033-0.04 Hz; LF, low-frequency 
power, 0.04-o. 15 Hz; HF, high-frequency power, 
0.15-0.40 Hz; TP, total-power, 0.0033-0.40 Hz; a 
ratio between the low- and high-frequency power, 
LF/HF. The physiological correlation to these indices 
is not fully understood. In a very simplified fashion 
LF is considered to mainly reflect sympathetic tone 
and HF is a marker for parasympathetic tone. 
The segments were computed to a mean of three 
defined time periods according to previous sugges- 
tions”, which were (1) a night period between mid- 
night and 5 am, (2) a day period between 7.30 am 
and 9.30 pm and (3) a 24-hour period. 
The study was approved by the Medical Ethics 
Committee of the Karolinska Institute and all sub- 
jects gave their informed consent. 
Statistical methods 
Data of the frequency domain components were log 
transformed, except the ratio of LF/HF, because their 
distribution was positively skewed. Data were fed into 
a Macintosh computer and processed in Microsoft Ex- 
cel (4.0) and Statview SE + Graphics (1.02). Differ- 
ences in conduction intervals and heart-rate variabil- 
ity variables between the last day on drug treatment 
and the following 4 days after drug withdrawal were 
tested using analysis of variance (ANOVA) for re- 
peated measures. 
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RESULTS 
No seizures were reported by the patients or the staff 
of the ward. 
Plasma concentrations 
The reduction in carbamazepine and phenytoin 
plasma levels after stopping drug treatment is shown 
in Fig. 1. 
Arrhythmia analyses 
Patient 3 had a 2:1 atria1 flutter with a heart rate of 
120 beats/minute, which was unaffected by the with- 
drawal of phenytoin. Five patients had changes in 
their arrhythmia profiles, shown by Fig. 2(a) and (b). 
Two patients (pts 4, 5) had a decrease in sinus pauses 
and in pt 10, the number of sinus pauses increased 
slightly from 550 episodes on day 1 to 683 episodes 
on day 5. In addition there was an increase of short 
runs of supraventricular tachycardias from 2 episodes 
on day 1 to 98 episodes on day 5, with a corre- 
sponding increase in posttachycardia pauses from 2 
to 63 episodes. Patient 8 had a decreasing number 
of episodes of second-degree atrioventricular block 
with 2: 1 conduction (from 17 episodes on day 1 to 
6 episodes on day 5). Three patients (pts 4.6, 10) had 
an increase in ventricular premature beats of > 10 
times. but no ventricular tachycardia was recorded. 
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Fig. 1: Plasma concentration of carbamazepine (n = 8; filled 
symbols) and phenytoin (n = 2; open symbols) measured as 
trough values at the end of the defined 24-hour period. Each 
line represents one patient. Day 1 represents the last day on 
a steady-state drug regimen before abrupt termination of drug 
therapy. 
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Fig. 2: These two figures show the change in arrhythmia pro- 
file from a steady-state drug concentration (day 1) and the 
following days after abrupt withdrawal of carbamazepine and 
phenytoin treatment, and each line represents one patient. (a) 
Ventricular premature beats (VPB) (filled symbols, for pts 4,6, 
10) and the numbers of short runs (5-15 beats) of supraven- 
tricular tachycardias (NT) in pt 10 (open symbols). (b) Sinus 
pauses (filled symbols, for pts 4, 5) and second-degree atri- 
oventricular block open symbols (for pt 8). 
Conduction intervals 
Two patients (pts 2, 10) had intraventricular conduc- 
tion defects, which were unaffected by withdrawal 
of the drugs. There was no statistically significant 
change in any variable analysed from day 1 to day 5. 
Heart-rate variability 
Nine patients were included in this analysis, while 
the patient with the atria1 flutter was excluded. Two 
patients (pts 4, 10) are represented with data up to 
the second and third day, respectively, since after 
that > 50% of the segments/day had to be excluded 
because of the increasing number of ventricular pre- 
mature beats; see arrhythmia analysis. There was no 
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Fig. 3: The changes in heart-rate variability in time and fre- 
quency domain from a steady-state condition with carba- 
mazepine and phenytoin treatment (day 1) and the follow- 
ing 4 days during abrupt drug withdrawal. (a) The time do- 
main variable, the SDNN index (ANOVA repeated measures 
P = 0.03). The y bars show the standard error of the mean. 
(b) Changes of the different components in the frequency do- 
main analyses for 24-hour values are presented. The following 
components in the power spectrum were significantly reduced 
during the study period. Total power (ANOVA repeated mea- 
sures, P = O.Ol), VLF = very-low-frequency power (ANOVA 
repeated measures, P = 0.004), LF = low-frequency power 
(ANOVA repeated measures, P = 0.01). There was no signif- 
icant reduction in the high frequency power (HF). The y bars 
show standard error of the mean. 
statistically significant change in mean 24-hour heart 
rate from day 1 to day 5. 
In the time domain the SDNN index decreased 
(ANOVA repeated measures, P = 0.03), Fig. 3(a). 
There was also a significant reduction of heart-rate 
variability in the frequency domain. The results were 
similar for the 24-hour, daytime and night-time analy- 
ses. Therefore only the 24-hour results are presented 
in Fig. 3(b) showing a significant reduction of TP, 
VLF, and LF, but no significant changes for HF dur- 
ing the withdrawal period. The ratio of LF/HF ex- 
pressed as a mean (fSEM) from days 1 and 5 were 
2.29 (0.44) and 2.68 (0.44) respectively (ANOVA re- 
peated measures were not significant). If the only 
remaining patient with phenytoin treatment was ex- 
cluded from the analysis the changes of the eight 
carbamazepine-treated patients remained significant. 
DISCUSSION 
Discussions on mechanisms behind SUD in epilepsy 
have previously been focused on seizure-related 
events. We point at drug-related non-ictal possible 
mechanisms. Our intention in this investigation was to 
study the autonomic modulation, by means of heart- 
rate variability analysis, and the arrhythmia profile 
during a drug situation similar to non-compliance 
which has been suggested to be associated with SUD. 
Arrhythmias 
Morganroth ef a1’8 defined the variability of ven- 
tricular premature beats in patients with a variety of 
cardiac-disease states and postulated that a more than 
IO-fold increase could be considered as a significant 
sign of a proarrhythmic development. Our study pop- 
ulation is different, but there is no reason to assume a 
higher spontaneous variability in ventricular prema- 
ture beats in these patients. A significant increase was 
thus observed in three of them. 
The majority of our patients were included due 
to a suspicion of a drug-induced bradycardia, and 
based on previous experience’ ‘, ” any depressant ef- 
fect on sinus node function and atrioventricular con- 
duction would presumably be partially or completely 
reversible. As anticipated a reduction of sinus pauses 
was also documented in two patients as well as a 
reduction of the episodes of second-degree atrioven- 
tricular block in the only patient with this conduction 
defect, Fig. 2(b). 
Heart-rate variability 
A significant reduction of the SDNN index in the 
time domain and TP, VLF, and LF in the frequency 
domain was found after drug withdrawal. A change 
in this direction was previously shown to predict all- 
cause mortality in post myocardial infarction popula- 
tions . “,” Interestingly the reduction of VLF power 
was most strongly associated with arrhythmic death 
rather than with all-cause mortality or cardiac death2’. 
The SDNN index, Fig. 3(a) in our study was lower 
on day 1 than values found in healthy individuals of 
similar age” and consequently, even lower at day 5. 
However, this time-domain index at day 5 was on the 
same level as in patients with ischaemic heart dis- 
ease”, but higher than in patients surviving a cardiac 
arrestZ2. 
In five of our patients a previous 24-hour ECG reg- 
istration had been performed on the same drug treat- 
ment and within the last 3 months. In these patients 
coefficient of variation was calculated for SDNN, TP, 
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VLF, I-IF and LF/HF indices, and was found to be 
around 10%. Day-to-day variation of heart rate is low 
in different subsets of patients and even lower in those 
with a reduced heart-rate variability (reviewed in 23). 
Mechanisms of sudden unexpected death in 
patients with epilepsy 
One interesting and unpredicted observation was the 
significant increase in ventricular premature beats in 
three patients, Fig. 2(a). Two of them (pts 4. 6) had 
no myocardial disease and withdrawal of these drugs 
was therefore not expected to be accompanied by an 
increased ventricular automaticity, unless drug with- 
drawal produced a rebound phenomenon, which has 
not previously been reported with these or similar 
drugs. 
Many authors have used repetitive ventricular pre- 
mature beats as an electrophysiological marker when 
studying the effects of psychological stress on car- 
diac vulnerability (reviewed in 24). Such electrical 
instability could be due to many neurogenic fac- 
tors, such as autonomic dysfunction, non-uniform pe- 
ripheral neural discharges, interictal activity or ictal 
epileptic activity (reviewed in 25). 
A more general observation in this study was the 
change in heart-rate variability. Normally this vari- 
ability is the consequence of a complex interaction 
between peripheral and central nervous system activ- 
ity . 26 Both drugs, however, have central as well as 
peripheral effects, although the design of our study 
does not allow any separation of the two. 
When it comes to the SUD issue both peripheral 
and central nervous imbalance might be of impor- 
tance in the development of ventricular arrhythmias. 
In animal studies instantaneous changes in both sym- 
pathetic and parasympathetic activity can induce fatal 
brady- or tachyarrhythmias (reviewed in 27, 5). A re- 
duction in heart-rate variability is considered to be 
equivalent to an impaired autonomic nervous balance 
and has been documented to be a predictor for an 
increased risk of sudden death in patients with dia- 
betic neuropathy, congestive heart failure and in post 
acute myocardial infarction’5* 1g,20*28-30. The occur- 
rence of even minimal interictal epileptogenic activ- 
ity can cause profound changes of centrally mediated 
autonomic activity and balance in animal studies (re- 
viewed in 5). The QT interval is influenced by auto- 
nomic changes and a significant increase in the heart- 
rate corrected QT interval has been demonstrated dur- 
ing epileptiform discharges in a group of patients, 
who later on suffered from SUD, compared to an age- 
matched control group of patients with epilepsy3t. 
There were no changes between the daily assessment 
of the heart-rate-corrected QT interval in our study. 
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However, due to the access of only two leads we 
were not able to analyse any changes in regional dif- 
ferences (dispersion) of the JT/QT intervals, which 
might be more important for arrythmogenesis than 
the single-lead QT interva13’. 
Limitations 
A selected group of patients with allergic or cardiac 
side effects justifying abrupt withdrawal of carba- 
mazepine or phenytoin was studied, and with an age 
range different from those patients with the highest 
risk for SUD in epilepsy. However, our group of pa- 
tients did not have an expected increased risk for ven- 
tricular arrhythmias, Table 1. 
The results should, however, not automatically be 
extrapolated to the epilepsy population in general and 
need confirmation. Our observations, however, reflect 
the intricate interactions between the nervous sys- 
tem, the cardiovascular system and ion-channel ac- 
tive drugs used to suppress electrical excitability, and 
what might happen in relation to sudden withdrawal 
of sodium-channel-blocking antiepileptic drugs. 
CONCLUSIONS 
This study demonstrates that abrupt withdrawal of 
antiepileptic treatment reduced heart-rate variability 
suggesting an altered autonomic modulation, which in 
other patient populations has been associated with in- 
creased mortalityt5* ‘g.20.22*2g*30. The withdrawal of 
these drugs induced an expected reduction in brady- 
cardias in a subgroup of patients. However, there 
was also an unexpected IO-fold increase in ventric- 
ular premature beats in some patients suggesting in- 
creased electrical instability. Since reduced heart-rate 
variability signals a state of increased electrical vul- 
nerability and ventricular premature beats might trig- 
ger life-threatening ventricular arrhythmias our ob- 
servations point to two important factors that might 
contribute to an increased risk for sudden death dur- 
ing abrupt withdrawal of sodium-channel-blocking 
antiepileptic drugs even in the absence of seizures. 
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